Richard Byrd serves as executive vice president and president of the Interventional Segment of BD (Becton, Dickinson and Company), a leading global medical technology company headquartered in Franklin Lakes, New Jersey. In this role, he is responsible for driving the global operational, commercial and financial performance of the three business units that comprise the Interventional Segment, including BD Peripheral Intervention, BD Surgery and BD Urology and Critical Care. He is also a member of the BD Executive Leadership Team.
Byrd most recently served as the worldwide president of BD Medication Delivery Solutions within the Medical segment. In that role, Byrd advanced BD’s leadership in Vascular Access Management, completing the integration of the Bard portfolio and driving a strong innovation pipeline. During the COVID-19 pandemic, he oversaw BD’s role in enabling global COVID-19 vaccination campaigns, including commitments of more than two billion injection devices worldwide. He also advanced BD’s “One-Stick Hospital Stay” vision to eliminate multiple needlesticks for in-patients and drive a new standard of care in vascular health.
Since joining BD in 2004, Byrd has demonstrated a proven track record of leveraging his strength in technology and innovation to drive growth while prioritizing customers’ needs, delivering operational efficiencies and developing talent across the globe. He previously held leadership roles within BD Life Sciences segment and Research and Development.
Byrd earned a master's degree in Mechanical Engineering from Stevens Institute of Technology and a Bachelor of Science degree in Mechanical Engineering from Virginia Tech.